KICK-IN GOAL LINKED TO WORST OF WITH EARLY REDEMPTION - NOVARTIS N/LONZA GROUP/ROCHE GS/GALENICA Share Price

Certificat

KPIEDU

CH1308768378

Market Closed - Swiss Exchange 16:20:00 13/06/2024 BST
100.8 CHF -0.10% Intraday chart for KICK-IN GOAL LINKED TO WORST OF WITH EARLY REDEMPTION - NOVARTIS N/LONZA GROUP/ROCHE GS/GALENICA
Date Price Change
13/06/24 100.8 -0.10%
10/06/24 100.9 -0.10%

Delayed Quote Swiss Exchange

Last update June 13, 2024 at 04:20 pm

More quotes

Static data

Product typeOther Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KPIEDU
ISINCH1308768378
Date issued 20/12/2023
Maturity 23/06/2025 (373 Days)
Parity 0.24 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 102.8 CHF
Lowest since issue 100.5 CHF
Spread 10.5 CHF
Spread %1.04%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus
  1. Stock Market
  2. Certificates
  3. KPIEDU Certificat
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW